PARKINSON DISEASE (Disorder)NCT07551661
Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease
A study testing Independent walking program using walking poles and Independent walking program without walking poles in people with PARKINSON DISEASE (Disorder), run by East Tennessee State University at 1 site in United States.
Trial summary
Study Purpose: The purpose of the study is to compare changes in walking in people with Parkinson disease after an 8-week independent walking program with or without using walking poles. Major parts of the Study: Before the walking program: Measurements will be taken of you while you are walking. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- PARKINSON DISEASE (Disorder)
- What is being tested?
- Independent walking program using walking poles and Independent walking program without walking poles
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2026to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- English-speaking, diagnosis of Parkinson disease, ability to walk safely and independently with or without a cane, and medically cleared to participate in an independent walking program. Participants must be physically present in the USA at the time of assessment.
Who cannot join
- diagnosis of any neurological disease other than PD (including but not limited to stroke, dementia, and multiple sclerosis; mild cognitive impairment is not excluded), regular (>30%) use of walking poles during walking for exercise for the prior 6 months, weight of more than 320 pounds or height more than 6'4", unable to participate in walking for more than 7 consecutive days during the study period (ie, traveling, scheduled surgery), anticipated change in Parkinson-specific medication (including additions, removals, or changes in dosage) during the intervention period, a change in deep brain stimulation (DBS) parameters during the intervention.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
East Tennessee State University
Johnson City, Tennessee, 37614
Tiffany Salido, PT, DPT, PhD, 423-439-8727, salido@etsu.edu
8284235390, salido@etsu.edu
About this study
Study Purpose: The purpose of the study is to compare changes in walking in people with Parkinson disease after an 8-week independent walking program with or without using walking poles.
Major parts of the Study:
Read more
Before the walking program: Measurements will be taken of you while you are walking. You will be given tests and questionnaires about your movement and thinking. You will be trained on how to use walking poles.
Independent walking program: You will be asked to walk at least 3 times each week for 8 weeks and keep a log of your walking. If you are in the walking pole group, you will walk with the poles. After the walking program: Your walking, movement, and thinking measurements will be collected as before the walking program.
Follow-up: The same measures of walking, movement, and thinking will be taken 3-months after ending the walking program.
Read the detailed description
Enrolled participants will complete the following Initial assessment
- Participant demographics will be collected and include age, weight, height, foot length, gender, years since diagnosis, daily Parkinson medication, deep brain stimulation status, and the following questions: "How many times have you fallen in the past 3 and 6 months?", "Are you comfortable using walking/hiking poles?" and "How many days per week do you participate in intentional exercise?"
- The Montreal Cognitive Assessment (MoCA) version 8.1 will be administered. If participant scores >18 (the cutoff score for mild cognitive impairment (MCI), they will continue in the study.
- The MDS-UPDRS Part III and Trail Making Test Part A and B will be administered.
- Outcome measures performed by walking on the GAITRite™ Walkway with Movella Xsens™ Bluetooth motion sensors (worn on upper back, lower back, arms, and legs) will include: 6-minute walk test (6 MWT), Timed-up-and go (TUG), TUG with a cognitive task, and the 10-meter walk test (10 MWT), and the Backward Walk Test. Heart rate will be collected with a Polar heart rate monitor chest strap during the 6-minute walk test.
- Self-reported outcome measure will include: Activities Specific Balance Confidence Scale (ABC Scale), Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Patient Questionnaire (Part IB and II), the Revised Oswestry Disability Index, and the Freezing of Gait Questionnaire.
- Participants will be trained on the use of walking poles, and then practice with the poles. The technique taught will be with the poles are held in front of the body, perpendicular to the ground, and swung in a reciprocal pattern. This initial training will last no more than 30 minutes and will include 10 minutes of independent pole practice.
Participants will return within a 14-day window for group or individual training walking with poles.
- Outcome measures performed on the GAITRite™ Walkway prior to training will include: 10 MWT with and without poles.
- Participant will train until they can demonstrate independent starting, >%50 correct technique and 100% self-correction within 3 missteps without cuing during 2 consecutive passes of 10 meters with a U-turn between passes.
- Participants will then perform 10 minutes of independent poling practice.
- Outcome measures performed on the GAITRite™ Walkway after training will include: 10 MWT with and without poles.
- After training and the gait assessment data are collected, the study group allocation will be revealed to each participant by a study member not involved in the assessment data collection.
- Participants randomized into the walking pole group will be provided with the poles for home use and asked to use the poles during all intentional walking for exercise during the study period. Pole use will not be restricted outside of the walking program.
The participants will participate in an independent walking program period for 8-weeks.
- All participants (intervention and control) will be asked to participate in at least 3 days of intentional walking exercise for the subsequent 8 weeks. Each participant will be given a log (see attached) to record their walking frequency and duration, rating of perceived exertion (RPE), notes, and any adverse events. Participants will be educated on the RPE scale and provided with a laminated RPE scale (see attached). All participants will be instructed to contact a designated study member via phone or email as soon as possible if an adverse event occurs. Events are defined as "Illness, injury, or falls" and contact information is provided on each page of the log.
- Participants will be contacted by a study member (see Check-in Script) by email (preferred) or phone (if participant does not use email or does not respond to email within 48 hours) at the end of weeks 1, 2, 4 and 6.
At conclusion of the 8-week walking program participants will return for reassessment.
- Walking logs will be collected.
- The MoCA version 8.2, MDS-UPDRS Part III and Trail Making Test Part A and B will be administered.
- Outcome measures performed by walking on the GAITRite™ Walkway with Movella Xsens™ Bluetooth motion sensors (worn on upper back, lower back, arms, and legs) will include: 6-minute walk test, Timed-up-and go (TUG), TUG with a cognitive task, and the 10-meter walk test with and without poles, and the Backward Walk Test. Heart rate will be collected with a Polar heart rate monitor chest strap during the 6-minute walk test.
- Self-reported outcome measure will include: Activities Specific Balance Confidence Scale (ABC Scale) and Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Patient Questionnaire (Part IB and II), the Revised Oswestry Disability Index, and the Freezing of Gait Questionnaire
- Participants in the control group will be provided a pair of walking poles for personal use.
Three-months following walking-program conclusion
- Self-reported outcome measure will include: Activities Specific Balance Confidence Scale (ABC Scale) and Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Patient Questionnaire (Part IB and II), the Revised Oswestry Disability Index, and the Freezing of Gait Questionnaire
- The MoCA version 8.3, MDS-UPDRS Part III and Trail Making Test Part A and B will be administered.
- Outcome measures performed by walking on the GAITRite™ Walkway with Movella Xsens™ Bluetooth motion sensors (worn on upper back, lower back, arms, and legs) will include: 6-minute walk test, Timed-up-and go (TUG), TUG with a cognitive task, and the 10-meter walk test with and without poles, and the Backward Walk Test. Heart rate will be collected with a Polar heart rate monitor chest strap during the 6-minute walk test.
- Participants will answer questions:
- "How many times have you fallen in the past 3 months?"
- "How often in the past month do you intentionally walk for exercise?"
- "What percentage in the past month do you use poles when intentionally walking for exercise?"
- "Please share any thoughts you would like the study team to know about your experience using walking poles."
- Conditions
- PARKINSON DISEASE (Disorder)
- Being tested
- Independent walking program using walking poles, Independent walking program without walking poles
- Keywords
- walking, physical activity, gait, Nordic walking, arm swing, walking poles
- Medical subject headings
- Parkinson Disease, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Independent walking program using walking polesBehavioural
Participants will independently walk at least 3 times a week for 8 weeks using walking poles
Independent walking program without walking polesBehavioural
Participants will independently walk at least 3 times a week for 8 weeks without walking poles
| Study group | Role | What they receive |
|---|---|---|
| Walking Poles | Experimental | Participants who will be using walking poles during the independent walking program Receives: Behavioral: Independent walking program using walking poles |
| No Walking Poles | Active comparator | Participants who will not be using walking poles during the independent walking program Receives: Behavioral: Independent walking program without walking poles |
What is being measured
The primary outcome is the main question the study is designed to answer.
Six Minute Walk Test
Measurement of distance walked in 6 minutes, a reflection of functional capacity.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Secondary outcomes (11)
Gait Characteristic - gait speed
Measure with a timed 10-meter walk test.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after completion.
Backward Walk Test
Timed 5-meter backward walking to gather backward gait speed.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Timed Up and Go
The Timed Up and Go (TUG) is a standardized measure of functional mobility, balance, and fall risk in adults. It captures how efficiently a person can transition between sitting, standing, walking, turning, and sitting again.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Cognitive Timed Up and Go
The Cognitive Timed Up and Go (TUG) is a standardized measure of functional mobility, balance, and fall risk in adults. It captures how efficiently a person can transition between sitting, standing, walking, turning, and sitting again while performing a cognitive task of counting backward by 3.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after completion.
Montreal Cognitive Assessment
The MoCA is a brief cognitive screening tool designed to detect mild cognitive impairment (MCI) and early cognitive decline.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
The MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The MDS-UPDRS is a clinical rating scale used to evaluate motor and non-motor symptoms in Parkinson's disease. We will be completing parts 1B, 2, and 3, which focus on patient-reported daily experiences and clinician-rated motor performance.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Activity-specific Balance Confidence Scale
Self-administered questionnaire that reflects the participant's confidence in their ability to maintain their balance while performing the 16 listed tasks. Score ranges from 0-100% and reflects overall % confidence. Lower scores indicate less confidence and thus worse outcome
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Arm swing
Arm swing data collected via inertial measurement unit (IMU) sensors on arms to measure angle and excursion; collected concurrently with 6MWT gait data.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Descriptive Gait Characteristics
Gait characteristics collected on gait walkway and via inertial measurement unit (IMU) sensors during gait tests, to include step length, step symmetry, and gait variability.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Freezing of Gait Questionnaire
A patient-reported measure that quantifies the severity, frequency, and functional impact of freezing of gait in people with Parkinson disease.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after the completion.
Revised Oswestry Disability Index
A self-report questionnaire that measures how low back pain affects functional ability in everyday life.
Measured: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after the completion.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2026
- Study startApr 2026 (estimated)
- Primary completionOct 2026 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Single center, two arm, pre-test post-test parallel design with 2 cohorts of participants.
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- East Tennessee State University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07551661
- Sponsor's protocol ID
- 0126.32f-ETSU
- Status last verified
- Apr 2026
- First submitted
- 20 Apr 2026
- Last updated
- 27 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD data will be shared.
Publications
Szefler-Derela J, Arkuszewski M, Knapik A, Wasiuk-Zowada D, Gorzkowska A, Krzystanek E. Effectiveness of 6-Week Nordic Walking Training on Functional Performance, Gait Quality, and Quality of Life in Parkinson's Disease. Medicina (Kaunas). 2020 Jul 17;56(7):356. doi: 10.3390/medicina56070356.
PubMed 32708938Salse-Batan J, Sanchez-Lastra MA, Suarez-Iglesias D, Varela S, Ayan C. Effects of Nordic walking in people with Parkinson's disease: A systematic review and meta-analysis. Health Soc Care Community. 2022 Sep;30(5):e1505-e1520. doi: 10.1111/hsc.13842. Epub 2022 May 20.
PubMed 35593147Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. J Aging Res. 2011;2011:232473. doi: 10.4061/2011/232473. Epub 2011 Mar 30.
PubMed 21603199Cugusi L, Manca A, Dragone D, Deriu F, Solla P, Secci C, Monticone M, Mercuro G. Nordic Walking for the Management of People With Parkinson Disease: A Systematic Review. PM R. 2017 Nov;9(11):1157-1166. doi: 10.1016/j.pmrj.2017.06.021. Epub 2017 Jul 8.
PubMed 28694221Mantri S, Fullard ME, Duda JE, Morley JF. Physical Activity in Early Parkinson Disease. J Parkinsons Dis. 2018;8(1):107-111. doi: 10.3233/JPD-171218.
PubMed 29480222Domingues VL, Pompeu JE, de Freitas TB, Polese J, Torriani-Pasin C. Physical activity level is associated with gait performance and five times sit-to-stand in Parkinson's disease individuals. Acta Neurol Belg. 2022 Feb;122(1):191-196. doi: 10.1007/s13760-021-01824-w. Epub 2021 Oct 23.
PubMed 34689319
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease
- ClinicalTrials.gov ID
- NCT07551661
- Acronym / sponsor ID
- 0126.32f-ETSU
- Conditions
- PARKINSON DISEASE (Disorder)
- Keywords
- walking, physical activity, gait, Nordic walking, arm swing, walking poles
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- East Tennessee State UniversityUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 27 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study Purpose: The purpose of the study is to compare changes in walking in people with Parkinson disease after an 8-week independent walking program with or without using walking poles.
Major parts of the Study:
Before the walking program: Measurements will be taken of you while you are walking. You will be given tests and questionnaires about your movement and thinking. You will be trained on how to use walking poles.
Independent walking program: You will be asked to walk at least 3 times each week for 8 weeks and keep a log of your walking. If you are in the walking pole group, you will walk with the poles. After the walking program: Your walking, movement, and thinking measurements will be collected as before the walking program.
Follow-up: The same measures of walking, movement, and thinking will be taken 3-months after ending the walking program.
Detailed description
Enrolled participants will complete the following Initial assessment
- Participant demographics will be collected and include age, weight, height, foot length, gender, years since diagnosis, daily Parkinson medication, deep brain stimulation status, and the following questions: "How many times have you fallen in the past 3 and 6 months?", "Are you comfortable using walking/hiking poles?" and "How many days per week do you participate in intentional exercise?"
- The Montreal Cognitive Assessment (MoCA) version 8.1 will be administered. If participant scores >18 (the cutoff score for mild cognitive impairment (MCI), they will continue in the study.
- The MDS-UPDRS Part III and Trail Making Test Part A and B will be administered.
- Outcome measures performed by walking on the GAITRite™ Walkway with Movella Xsens™ Bluetooth motion sensors (worn on upper back, lower back, arms, and legs) will include: 6-minute walk test (6 MWT), Timed-up-and go (TUG), TUG with a cognitive task, and the 10-meter walk test (10 MWT), and the Backward Walk Test. Heart rate will be collected with a Polar heart rate monitor chest strap during the 6-minute walk test.
- Self-reported outcome measure will include: Activities Specific Balance Confidence Scale (ABC Scale), Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Patient Questionnaire (Part IB and II), the Revised Oswestry Disability Index, and the Freezing of Gait Questionnaire.
- Participants will be trained on the use of walking poles, and then practice with the poles. The technique taught will be with the poles are held in front of the body, perpendicular to the ground, and swung in a reciprocal pattern. This initial training will last no more than 30 minutes and will include 10 minutes of independent pole practice.
Participants will return within a 14-day window for group or individual training walking with poles.
- Outcome measures performed on the GAITRite™ Walkway prior to training will include: 10 MWT with and without poles.
- Participant will train until they can demonstrate independent starting, >%50 correct technique and 100% self-correction within 3 missteps without cuing during 2 consecutive passes of 10 meters with a U-turn between passes.
- Participants will then perform 10 minutes of independent poling practice.
- Outcome measures performed on the GAITRite™ Walkway after training will include: 10 MWT with and without poles.
- After training and the gait assessment data are collected, the study group allocation will be revealed to each participant by a study member not involved in the assessment data collection.
- Participants randomized into the walking pole group will be provided with the poles for home use and asked to use the poles during all intentional walking for exercise during the study period. Pole use will not be restricted outside of the walking program.
The participants will participate in an independent walking program period for 8-weeks.
- All participants (intervention and control) will be asked to participate in at least 3 days of intentional walking exercise for the subsequent 8 weeks. Each participant will be given a log (see attached) to record their walking frequency and duration, rating of perceived exertion (RPE), notes, and any adverse events. Participants will be educated on the RPE scale and provided with a laminated RPE scale (see attached). All participants will be instructed to contact a designated study member via phone or email as soon as possible if an adverse event occurs. Events are defined as "Illness, injury, or falls" and contact information is provided on each page of the log.
- Participants will be contacted by a study member (see Check-in Script) by email (preferred) or phone (if participant does not use email or does not respond to email within 48 hours) at the end of weeks 1, 2, 4 and 6.
At conclusion of the 8-week walking program participants will return for reassessment.
- Walking logs will be collected.
- The MoCA version 8.2, MDS-UPDRS Part III and Trail Making Test Part A and B will be administered.
- Outcome measures performed by walking on the GAITRite™ Walkway with Movella Xsens™ Bluetooth motion sensors (worn on upper back, lower back, arms, and legs) will include: 6-minute walk test, Timed-up-and go (TUG), TUG with a cognitive task, and the 10-meter walk test with and without poles, and the Backward Walk Test. Heart rate will be collected with a Polar heart rate monitor chest strap during the 6-minute walk test.
- Self-reported outcome measure will include: Activities Specific Balance Confidence Scale (ABC Scale) and Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Patient Questionnaire (Part IB and II), the Revised Oswestry Disability Index, and the Freezing of Gait Questionnaire
- Participants in the control group will be provided a pair of walking poles for personal use.
Three-months following walking-program conclusion
- Self-reported outcome measure will include: Activities Specific Balance Confidence Scale (ABC Scale) and Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Patient Questionnaire (Part IB and II), the Revised Oswestry Disability Index, and the Freezing of Gait Questionnaire
- The MoCA version 8.3, MDS-UPDRS Part III and Trail Making Test Part A and B will be administered.
- Outcome measures performed by walking on the GAITRite™ Walkway with Movella Xsens™ Bluetooth motion sensors (worn on upper back, lower back, arms, and legs) will include: 6-minute walk test, Timed-up-and go (TUG), TUG with a cognitive task, and the 10-meter walk test with and without poles, and the Backward Walk Test. Heart rate will be collected with a Polar heart rate monitor chest strap during the 6-minute walk test.
- Participants will answer questions:
- "How many times have you fallen in the past 3 months?"
- "How often in the past month do you intentionally walk for exercise?"
- "What percentage in the past month do you use poles when intentionally walking for exercise?"
- "Please share any thoughts you would like the study team to know about your experience using walking poles."
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Single center, two arm, pre-test post-test parallel design with 2 cohorts of participants.
| Arm | Type | Receives |
|---|---|---|
| Walking Poles | Experimental | Behavioral: Independent walking program using walking polesParticipants who will be using walking poles during the independent walking program |
| No Walking Poles | Active comparator | Behavioral: Independent walking program without walking polesParticipants who will not be using walking poles during the independent walking program |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- English-speaking, diagnosis of Parkinson disease, ability to walk safely and independently with or without a cane, and medically cleared to participate in an independent walking program. Participants must be physically present in the USA at the time of assessment.
Key exclusion criteria (1 listed)
- diagnosis of any neurological disease other than PD (including but not limited to stroke, dementia, and multiple sclerosis; mild cognitive impairment is not excluded), regular (>30%) use of walking poles during walking for exercise for the prior 6 months, weight of more than 320 pounds or height more than 6'4", unable to participate in walking for more than 7 consecutive days during the study period (ie, traveling, scheduled surgery), anticipated change in Parkinson-specific medication (including additions, removals, or changes in dosage) during the intervention period, a change in deep brain stimulation (DBS) parameters during the intervention.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Independent walking program using walking polesParticipants will independently walk at least 3 times a week for 8 weeks using walking poles | Behavioural | Walking Poles |
| Independent walking program without walking polesParticipants will independently walk at least 3 times a week for 8 weeks without walking poles | Behavioural | No Walking Poles |
Primary outcome
Six Minute Walk Test
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Measurement of distance walked in 6 minutes, a reflection of functional capacity.
11 secondary outcomes
Gait Characteristic - gait speed
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after completion.
Backward Walk Test
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Timed Up and Go
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Cognitive Timed Up and Go
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after completion.
Montreal Cognitive Assessment
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
The MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Activity-specific Balance Confidence Scale
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Arm swing
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Descriptive Gait Characteristics
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.
Freezing of Gait Questionnaire
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after the completion.
Revised Oswestry Disability Index
Time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3-months after the completion.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2026.
- Results publication: PubMed 32708938Szefler-Derela J, Arkuszewski M, Knapik A, Wasiuk-Zowada D, Gorzkowska A, Krzystanek E. Effectiveness of 6-Week Nordic Walking Training on Functional Performance, Gait Quality, and Quality of Life in Parkinson's Disease. Medicina (Kaunas). 2020 Jul 17;56(7):356. doi: 10.3390/medicina56070356.
- Results publication: PubMed 35593147Salse-Batan J, Sanchez-Lastra MA, Suarez-Iglesias D, Varela S, Ayan C. Effects of Nordic walking in people with Parkinson's disease: A systematic review and meta-analysis. Health Soc Care Community. 2022 Sep;30(5):e1505-e1520. doi: 10.1111/hsc.13842. Epub 2022 May 20.
- Results publication: PubMed 21603199Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. J Aging Res. 2011;2011:232473. doi: 10.4061/2011/232473. Epub 2011 Mar 30.
- Results publication: PubMed 28694221Cugusi L, Manca A, Dragone D, Deriu F, Solla P, Secci C, Monticone M, Mercuro G. Nordic Walking for the Management of People With Parkinson Disease: A Systematic Review. PM R. 2017 Nov;9(11):1157-1166. doi: 10.1016/j.pmrj.2017.06.021. Epub 2017 Jul 8.
- Results publication: PubMed 29480222Mantri S, Fullard ME, Duda JE, Morley JF. Physical Activity in Early Parkinson Disease. J Parkinsons Dis. 2018;8(1):107-111. doi: 10.3233/JPD-171218.
- Results publication: PubMed 34689319Domingues VL, Pompeu JE, de Freitas TB, Polese J, Torriani-Pasin C. Physical activity level is associated with gait performance and five times sit-to-stand in Parkinson's disease individuals. Acta Neurol Belg. 2022 Feb;122(1):191-196. doi: 10.1007/s13760-021-01824-w. Epub 2021 Oct 23.
- Individual participant dataSharing planned: Yes. All IPD data will be shared.
Related trials for PARKINSON DISEASE (Disorder)
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Independent walking program using walking poles and Independent walking program without walking poles in people with PARKINSON DISEASE (Disorder), run by East Tennessee State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tiffany Salido, PT, DPT, PhD (423-439-8727, salido@etsu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Six Minute Walk Test (time frame: Prior to initiation of 8 week walking program, immediately upon completion, and 3 months after completion.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07551661, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2026.